MedPath

RG2417

Generic Name
RG2417
Drug Type
Small Molecule
Background

RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential for cell metabolism. Uridine is synthesized by the mitochondria, the power plant of the human cell responsible for energy metabolism. The rationale for uridine therapy in neuropsychiatric disorders is supported by preclinical and clinical research. Recent reports indicate that certain genes that encode for mitochondrial proteins are significantly down regulated in the brains of bipolar patients. This new insight suggests that the symptoms of bipolar disorder may be linked to dysregulation of energy metabolism of the brain.

Indication

Investigated for use/treatment in bipolar disorders and manic disorders.

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

Phase 2
Completed
Conditions
Bipolar I Depression
Interventions
Drug: Placebo
First Posted Date
2008-12-19
Last Posted Date
2011-01-17
Lead Sponsor
Repligen Corporation
Target Recruit Count
180
Registration Number
NCT00812058
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

🇺🇸

Western Psychiatric Institute Clinic, Pittsburg, Pennsylvania, United States

and more 33 locations
© Copyright 2025. All Rights Reserved by MedPath